-

KARL STORZ Endoscopy-America Announces Appointment of New Managing Director

EL SEGUNDO, Calif.--(BUSINESS WIRE)--KARL STORZ Endoscopy-America, Inc. (KSEA), a leader in endoscopic imaging and related minimally invasive surgical systems, announced today that Sonal Matai has been appointed Managing Director. A visionary medtech leader, Matai will succeed Charlie Wilhelm, who departs KSEA after 30 years with the company and on the heels of a record performance year.

“I am incredibly excited to be joining KSEA during this period of innovation and rapid market share growth,” said Matai. “I look forward to building on the solid foundation established by Charlie and his leadership team as we continue our focus on delivering meaningful value to providers and patients.” Matai brings a unique perspective to his new role, having worked in senior commercial, marketing, and strategy positions at Philips and GE in the USA, Netherlands, Thailand, and India. In his last role at Philips, he was the North American Business Leader for Philips’ Sleep and Respiratory Care business, which included the Sleep Apnea, Home Ventilation, Hospital Ventilation, and RespirTech business lines. Matai’s tenure in the healthcare industry and deep understanding of customer needs will be an asset to KSEA as the company charts its course for the future. Matai has a Post Graduate Diploma in Management from IMT, Ghaziabad, India, and an MBA from IMD Business School, Lausanne, Switzerland.

About KARL STORZ

KARL STORZ Endoscopy-America, Inc., is an affiliate of KARL STORZ SE & Co. KG, an international leader for more than 75 years in reusable endoscope technology, encompassing all endoscopic specialties. Based in Tuttlingen, Germany, KARL STORZ SE & Co. KG is a family-owned company that designs, engineers, manufactures, and markets all its products with an emphasis on visionary design, precision craftsmanship, and clinical effectiveness. For more information, call 800-421-0837 or visit the company’s website at www.karlstorz.com.

Contacts

Anja Ebert
Corporate Communications
KARL STORZ
+011-4974617082607

KARL STORZ Endoscopy-America, Inc.


Release Summary
Sonal Matai has assumed the top management role at KARL STORZ Endoscopy-America.
Release Versions

Contacts

Anja Ebert
Corporate Communications
KARL STORZ
+011-4974617082607

Social Media Profiles
More News From KARL STORZ Endoscopy-America, Inc.

ADDING MULTIMEDIA KARL STORZ Announces FDA Clearance for ENDOFLATOR + Insufflator and Smoke Evacuation System

EL SEGUNDO, Calif.--(BUSINESS WIRE)--KARL STORZ, a global leader in minimally invasive surgical technology, is proud to announce it has received U.S. Food and Drug Administration (FDA) clearance for the ENDOFLATOR™ +. ENDOFLATOR + is the next-generation insufflator with integrated surgical smoke evacuation system designed to meet the evolving needs of modern operating rooms. Using carbon dioxide gas, an insufflator establishes and maintains a stable working cavity within the body during laparos...

KARL STORZ Unifies Canada, US, and Veterinary Organizations to Form North America Region Led by Sonal Matai

EL SEGUNDO, Calif.--(BUSINESS WIRE)--KARL STORZ, a family-owned medical technology company headquartered in Tuttlingen, Germany, today announced the creation of a North America region that unifies its US, Canada, and Veterinary businesses under the leadership of Sonal Matai. Matai joined KARL STORZ in 2022 and was appointed to lead KARL STORZ United States in early 2024. As President of North America, Matai will now oversee key functions such as commercial operations, research and development,...

AventaMed, a KARL STORZ Company, Receives Expanded Indication for Solo+ Tympanostomy Tube Device (TTD)

EL SEGUNDO, Calif.--(BUSINESS WIRE)--KARL STORZ United States is proud to announce that the US Food and Drug Administration (FDA) has cleared an expanded indication for the AventaMed Solo+™ Tympanostomy Tube Device (TTD), allowing its use in pediatric patients aged 6 months and older. This expanded clearance builds on the previous 510(k) clearance, which was indicated for patients 6 to 24 months old. The Solo+ device represents a significant advancement in pediatric ENT care. It is intended to...
Back to Newsroom